178 related articles for article (PubMed ID: 23617421)
1. Focusing on boron in medicinal chemistry.
Ramachandran PV
Future Med Chem; 2013 Apr; 5(6):611-2. PubMed ID: 23617421
[No Abstract] [Full Text] [Related]
2. Boron chemicals in diagnosis and therapeutics.
Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
[TBL] [Abstract][Full Text] [Related]
3. The persisting challenge of selective and specific proteasome inhibition.
Groll M; Huber R; Moroder L
J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors for multiple myeloma].
Yano H; Iida S
Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
[No Abstract] [Full Text] [Related]
5. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Huber EM; Groll M
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
[TBL] [Abstract][Full Text] [Related]
6. Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925
[No Abstract] [Full Text] [Related]
7. The proteasome--an emerging therapeutic target in cancer.
Mitchell BS
N Engl J Med; 2003 Jun; 348(26):2597-8. PubMed ID: 12826633
[No Abstract] [Full Text] [Related]
8. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
9. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
10. Not boring at all. Boron is the new carbon in the quest for novel drug candidates.
Hunter P
EMBO Rep; 2009 Feb; 10(2):125-8. PubMed ID: 19182828
[No Abstract] [Full Text] [Related]
11. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
[No Abstract] [Full Text] [Related]
12. Concurrent radiation therapy and bortezomib in myeloma patient.
Berges O; Decaudin D; Servois V; Kirova YM
Radiother Oncol; 2008 Feb; 86(2):290-2. PubMed ID: 18199515
[No Abstract] [Full Text] [Related]
13. [Classification and synthesis of ubiquitin-proteasome inhibitor].
Li J; Zhang DY; Wu XM
Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462
[TBL] [Abstract][Full Text] [Related]
14. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
15. [Bortezomib].
Simons S; Scheulen ME; Jaehde U
Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
[No Abstract] [Full Text] [Related]
16. Bortezomib: a novel therapy approved for multiple myeloma.
Richardson PG; Anderson KC
Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition and multiple myeloma.
Kanagasabaphy P; Morgan GJ; Davies FE
Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
[TBL] [Abstract][Full Text] [Related]
18. [Development and clinical application of novel proteasome inhibitors].
Iida S
Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
[No Abstract] [Full Text] [Related]
19. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
20. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
